Nervous system and Fabry disease, from symptoms to diagnosis: Damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy

Neurological Sciences

Volumn 31, Issue 3, 2010, Pages 299-306

  Salviati, Alessandro ^a   Burlina, Alessandro P ^b   Borsini, Walter ^c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b San Bassiano Hospital   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Enzyme replacement therapy; Fabry; Globotriaosylceramide; Small fiber neuropathy

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CARBAMAZEPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GABAPENTIN;

ADULT; CHROMOSOME INACTIVATION; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DNA DETERMINATION; DOSE RESPONSE; EARLY DIAGNOSIS; ENZYME ASSAY; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; GENETIC ANALYSIS; HOME CARE; HUMAN; NERVE CONDUCTION; NEUROIMAGING; NEUROPATHIC PAIN; ORGAN INJURY; PATIENT MONITORING; PHYSICIAN ATTITUDE; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; SKIN BIOPSY; TREATMENT PLANNING; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; NEUROLOGIC DISEASE; PATHOLOGY; PRACTICE GUIDELINE;

DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; HUMANS; NERVOUS SYSTEM DISEASES;

EID: 77955896908     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-009-0211-y     Document Type: Review

References (51)

1. Brady RO, Gal aE, Bradley RM, Martensonn E, Warshaw aL, Laster L (1967) Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. New Engl J Med 276:1163-1167
2. Desnick RJ, Ioannou Ya, Eng ME (2001) a-Galactosidase a deficiency: Fabry disease. In: Scriver CR, Beaudet aL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease, vol 3, 8th edn. McGraw-Hill, New York, pp 3733-3774
3. MacDermot KD, Holmes a, Miners aH (2001) anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750-760 (Pubitemid 33032930)
4. Mehta a, Widmer U (2006) Natural history of Fabry disease. In: Mehta a, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford Pharmagenesis, Oxford, pp 183-188
5. Mehta a, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo a, Kampmann C, Linhart a, Sunder-Plassmann G, Ries M, Beck M (2004) Fabry disease defined: baseline clinical manifestations of 336 patients in the Fabry outcome survey. Eur J Clin Invest 34:236-242
6. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184-192
7. Buechner S, Moretti M, Burlina aP, Cei G, Manara R, Ricci R, Mignani R, Parini R, Di Vito R, Giordano GP, Simonelli P, Siciliano G, Borsini W (2008) Central nervous system involvement in anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 79:1249-1254
8. Fellgiebel a, Müller MJ, Ginsberg L (2006) CNS manifestations of Fabry's disease. Lancet Neurol 5:791-795
9. Møller aT, Jensen TS (2007) Neurological manifestations in Fabry's disease. Nat Clin Pract Neurol 3:95-106
10. Lidove O, Chauveheid MP, Caillaud C, Froissart R, Benoist L, alamowitch S, Doan S, Szalat R, Baumann N, alexandra JF, Lavallée P, Klein I, Vuillemet F, Sedel F, Sacré K, Samson Y, Roullet E, Papo T (2009) aseptic meningitis and ischemic stroke in Fabry disease. Int J Clin Pract 63:1663-1667
11. Invernizzi P, Bonometti Ma, Turri E, Benedetti MD, Salviati a (2008) a case of Fabry disease with central nervous system (CNS) demyelinating lesions: a double trouble? Mult Scler 14:1003-1006
12. Clavelou P, Besson G (2007) Neurological aspects of Fabry disease. Presse Med 36 Spec No 1:1S65-S68
13. Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65-77
14. Low M, Nicholls K, Tubridy N, Hand P, Velakoulis D, Kiers L, Mitchell P, Becker G (2007) Neurology of Fabry disease. Intern Med J 37:436-447
15. Laaksonen SM, Röyttä M, Jääskeläinen SK, Kantola I, Penttinen M, Falck B (2008) Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol 119:1365-1372
16. Liguori R, Di Stasi V, Bugiardini E, Mignani R, Burlina a, Borsini W, Baruzzi a, Montagna P, Donadio V (2009) Small fiber neuropathy in female patients with Fabry disease. Muscle Nerve 41:409-412
17. Conti G, Sergi B (2003) auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous female. acta Paediatr 92(Suppl 443):33-37
18. Fellgiebel a, Mü ller MJ, Mazanek M, Baron K, Beck M, Stoeter P (2005) White matter lesion severity in male and female patients with Fabry disease. Neurology 65:600-602
19. Ginsberg L, Manara R, Valentine aR, Kendall B, Burlina aP (2006) Magnetic resonance imaging changes in Fabry disease. acta Paediatr 95(Suppl 451):57-62
20. Burlina aP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, Burlina a, Lidove O (2008) The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 255:738-744
21. Rolfs a, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Löhr M, Harzer K, Strauss U, Pahnke J, Grossmann a, Benecke R (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794-1796
22. Fellgiebel a, Keller I, Marin D, Müller MJ, Schermuly I, Yakushev I, Bellhäuser H, Kinateder M, Beck M, Stoeter P (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72:63-68
23. Moore DF, altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, Charria-Ortiz G, Ferri R, arai aE, Brady RO, Schiffmann R (2002) Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33:525-531
24. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251:564-570
25. Buechner S, Luzzi C, Mannucci M, Massi D, Borsini W (2006) Diagnosis of anderson-Fabry's disease in over seventy yearold women: description of two cases. aging Clin Exp Res 18:340-343
26. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, International Fabry Disease Study Group (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. am J Hum Genet 75:65-74
27. Desnick RJ, Brady R, Barranger J, Collins aJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. ann Intern Med 138:338-346
28. Rankin J (1957) Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 2:200-215
29. The EuroQol Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
30. Whybra C, Bähner F, Baron K (2006) Measurement of disease severity and progression in Fabry disease. In: Mehta a, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford Pharmagenesis, Oxford, pp 315-322
31. Lidove O, Joly D, Barbey F, Bekri S, alexandra JF, Peigne V, Jaussaud R, Papo T (2007) Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 61:293-302
32. Schaefer RM, Tylki-Szymanska a, Hilz MJ (2009) Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 69:2179-2205
33. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539-548
34. Lubanda JC, anijalg E, Bzdúch V, Thurberg BL, Bénichou B, Tylki-Szymanska a (2009) Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 11:256-264
35. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Fabry Disease Clinical Trial Study Group (2007) agalsidase-beta therapy for advanced Fabry disease: a randomized trial. ann Intern Med 146:77-86
36. Hughes Da, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta aB (2008) Effects of enzyme replacement therapy on the cardiomyopathy of anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153-158
37. Parini R, Rigoldi M, Santus F, Furlan F, De Lorenzo P, Valsecchi G, Concolino D, Strisciuglio P, Feriozzi S, Di Vito R, Ravaglia R, Ricci R, Morrone a (2008) Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with anderson- Fabry disease: testing the effects with the Mainz Severity Score Index. Clin Genet 74:260-266
38. Spinelli L, Pisani a, Sabbatini M, Petretta M, andreucci MV, Procaccini D, Lo Surdo N, Federico S, Cianciaruso B (2004) Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 66:158-165
39. Hajioff D, Hegemann S, Conti G, Beck M, Sunder-Plassmann G, Widmer U, Mehta a, Keilmann a (2006) agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 36:663-667 (Pubitemid 44213834)
40. Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M (2004) Enzyme replacement therapy improves function of C-, adelta-, and abeta-nerve fibers in Fabry neuropathy. Neurology 62:1066-1072
41. Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta a, European Investigators FOS (2007) Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy-a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 23:535-542
42. Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703-710
43. Schiffmann R, Hauer P, Freeman B, Ries M, Scott LJ, Polydefkis M, Brady RO, Mcarthur JC, Wagner K (2006) Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 34:53-56
44. Cousins a, Lee P, Rorman D, Raas-Rothschild a, Banikazemi M, Waldek S, Thompson L (2008) Home-based infusion therapy for patients with Fabry disease. Br J Nurs 17:653-657
45. Hughes Da, Mlilligan a, Mehta a (2007) Home therapy for lysosomal storage disorders. Br J Nurs 16:1384, 1386-1389
46. Linthorst GE, Vedder aC, Ormel EE, aerts JM, Hollak CE (2006) Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands. Nephrol Dial Transplant 21:355-360
47. Filling-Katz MR, Merrick HF, Fink JK, Miles RB, Sokol J, Barton NW (1989) Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 39:598-600
48. Ries M, Mengel E, Kutschke G, Kim KS, Birklein F, Krummenauer F, Beck M (2003) Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 26:413-414
49. Schreiber W, Udvardi a, Kristoferitsch W (2007) Chronic meningitis and lacunar stroke in Fabry disease. J Neurol 254:1447-1449
50. Caraceni a, Mendoza TR, Mencaglia E, Baratella C, Edwards K, Forjaz MJ, Martini C, Serlin RC, de Conno F, Cleeland CS (1996) a validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 65:87-92
51. Melzack R (1987) The short-form McGill Pain Questionnaire. Pain 30:191-197